Skip to main content
OpenTrials
Completed

NCT Number: NCT06393309

Levetiracetam Versus Valproate in Idiopathic Generalized Epilepsy

This study aimed to compare the long-term efficacy and safety of levetiracetam and valproate in treatment of idiopathic generalized epilepsy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Treatment of Idiopathic Generalized Epilepsy Epilepsy, Idiopathic Generalized

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Bu Ali Sina Hospital

Sari, Mazandaran, 4815837477, Iran

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of juvenile myoclonic epilepsy or generalized tonic-clonic seizure alone
  • Regular monotherapy with levetiracetam or sodium valproate

Exclusion criteria

  • Poor drug adherence
  • Pregnancy

Treatment and study plan

Levetiracetam

Drug

Patients with idiopathic generalized epilepsy who were under treatment with levetiracetam

Sodium Valproate

Drug

Patients with idiopathic generalized epilepsy who were under treatment with valproate

Primary outcomes

  1. Seizure free rate

    Time frame: 1 to 5 years

    The percent of patients who remained seizure free on treatment

  2. Time to first seizure

    Time frame: 1 to 5 years

    The interval between start of treatment and recurrence of seizure

Secondary outcomes

  1. Retention rate

    Time frame: 1 to 5 years

    The percent of patients who remained on treatment with levetiracetam or valproate

  2. Time to withdrawal

    Time frame: 1 to 5 years

    The interval between start and withdrawal of treatment

Sponsors and collaborators

Lead sponsor

Mazandaran University of Medical Sciences

Other

Registry information

Official study title

Investigation of Long-term Outcome of Levetiracetam and Valproate in Treatment of Idiopathic Generalized Epilepsy

Acronym: LEVAGE

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
May 1, 2024
Registry last updated
May 2, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.